### Supplementary File 2 STARPA trial safety outcomes

|                          | Atorvastatin (n=31) | Placebo (n=31) |
|--------------------------|----------------------|----------------|
| **Self-reported side effects** |                      |                |
| Muscle cramps or pain    | 10                   | 10             |
| Gastrointestinal symptoms| 5                    | 4              |
| Skin and subcutaneous symptoms | 4         | 2              |
| Sleep problems           | 0                    | 3              |
| Cough                    | 1                    | 3              |
| **Laboratory abnormalities** |                      |                |
| ALT elevation >3x ULN    | 3                    | 0              |
| CK >3x ULN               | 2                    | 0              |
| **Adverse events other, according to ICD-10 chapter** |              |                |
| Infectious and parasitic disease | 9            | 8              |
| Neoplasms                | 1*                   | 0              |
| Blood and blood-forming organs and immune system disease | 1 | 2 |
| Endocrine, nutritional, and metabolic disease | 1 | 1* |
| Mental and behavioral disorder | 0            | 1              |
| Nervous system           | 1                    | 1              |
| Eye and adnexa           | 0                    | 3              |
| Respiratory disease      | 1                    | 4              |
| Digestive system         | 2                    | 1              |
| Musculoskeletal and connective tissue disease | 1 | 1 |
| Genitourinary system disease | 1            | 1              |
| Symptoms, signs, and abnormal clinical and laboratory findings not classified elsewhere | 2 | 3 |
| Injury                   | 3                    | 1              |
| None                     | 8                    | 11             |

* Serious adverse event. Diagnosis metastasized colon carcinoma

† = Serious adverse event. One night of hospitalization due to abdominal pain, not diagnosed

Both SAEs were not considered to be related to trial medication.

ULN: upper limit of normal